Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells
- PMID: 15870945
Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells
Abstract
We investigated the effect of the vasoactive intestinal (VIP) and pituitary adenylate cyclase activating peptides (PACAP) on the production of interleukin-6 (IL-6) in normal prostate epithelial and stromal cells and prostate cancer cells. We performed RT-PCR analysis to assess the expression of VIP receptor (VPAC1, VPAC2 and PAC1) mRNA in normal prostate epithelial and stromal cells and prostate cancer cells, and investigated the effect of VIP and PACAP on the production of IL-6. VPAC1, VPAC2 and PAC1 receptor mRNAs were expressed in LNCaP and DU-145/AR prostate cancer cells and PrEC cells (prostate epithelial cells). VIP stimulated the production of IL-6 in DU-145/AR prostate cancer and PrEC cells. PACAP showed a similar effect on IL-6 production in PrEC cells. VIP stimulated IL-6 promoter transcriptional activity in DU-145/AR cells. These results indicate that VIP and PACAP may modulate the IL-6 production of normal prostate epithelial and prostate cancer cells.
Similar articles
-
Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.Reproduction. 2007 Aug;134(2):281-92. doi: 10.1530/REP-07-0051. Reproduction. 2007. PMID: 17660238
-
Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.Gynecol Endocrinol. 2005 Jun;20(6):327-33. doi: 10.1080/09513590500098240. Gynecol Endocrinol. 2005. PMID: 16019382
-
VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.Endocrinology. 2005 Feb;146(2):744-50. doi: 10.1210/en.2004-0504. Epub 2004 Oct 28. Endocrinology. 2005. PMID: 15514088
-
Role of VIP and PACAP in islet function.Peptides. 2007 Sep;28(9):1805-13. doi: 10.1016/j.peptides.2007.04.024. Epub 2007 May 6. Peptides. 2007. PMID: 17559974 Review.
-
Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.Kaibogaku Zasshi. 2000 Dec;75(6):487-507. Kaibogaku Zasshi. 2000. PMID: 11197592 Review.
Cited by
-
Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.Psychoneuroendocrinology. 2013 Dec;38(12):2983-95. doi: 10.1016/j.psyneuen.2013.08.008. Epub 2013 Sep 6. Psychoneuroendocrinology. 2013. PMID: 24054763 Free PMC article.
-
Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.J Mol Neurosci. 2014 Jan;52(1):28-36. doi: 10.1007/s12031-013-0193-3. Epub 2013 Dec 10. J Mol Neurosci. 2014. PMID: 24323361
-
Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.PLoS One. 2011;6(11):e28304. doi: 10.1371/journal.pone.0028304. Epub 2011 Nov 30. PLoS One. 2011. PMID: 22140573 Free PMC article.
-
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.Am J Clin Exp Urol. 2014 Oct 2;2(3):231-8. eCollection 2014. Am J Clin Exp Urol. 2014. PMID: 25374925 Free PMC article. Review.
-
Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization.Curr Protein Pept Sci. 2024;25(6):480-491. doi: 10.2174/0113892037287189240122110819. Curr Protein Pept Sci. 2024. PMID: 38284716
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials